Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 11/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20415191 | 0.94 | PRKDC (0.43) | PRKDCSYKROCK2ROCK1 | |
| SCHEMBL17634663 | 0.94 | PRKDC (0.47) | PRKDCSYKDYRK1ACLK2CLK3 | |
| SCHEMBL19355627 | 0.90 | PRKDC (0.40) | PRKDCROCK2ROCK1 | |
| SCHEMBL19905037 | 0.89 | PRKDC (0.42) | PRKDCPRMT5WDR77 | |
| SCHEMBL19355565 | 0.88 | PRKDC (0.41) | PRKDCDYRK1A | |
| SCHEMBL19905265 | 0.88 | SYK (0.39) | SYKDYRK1ACLK2CLK3ROCK2 | |
| SCHEMBL17634654 | 0.88 | PRKDC (0.51) | PRKDCSYK | |
| SCHEMBL17874739 | 0.87 | PRKDC (0.48) | PRKDCPRMT5WDR77GSK3B | |
| SCHEMBL19905467 | 0.87 | PRKDC (0.48) | PRKDCPRMT5WDR77GSK3B | |
| SCHEMBL17874726 | 0.87 | PRKDC (0.46) | PRKDCSYKPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258789-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258789-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PRKDC 33/4885SYK 2672/4885DYRK1A 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.